This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD); amyotrophic lateral sclerosis (ALS)	Amyloid precursor protein (APP); chromogranin B (CHGB); neuregulin 1 (NRG1); α -synuclein (SNCA)	<p>Mouse and human studies suggest measuring the transport rates of CNS proteins into and out of cerebrospinal fluid (CSF) could help diagnose PD and ALS. In CSF from mouse models for ALS pretreated with heavy water ($^2\text{H}_2\text{O}$), rates of appearance and disappearance of ^2H-labeled Chgb, Nrg1 and soluble App were lower than those for healthy $^2\text{H}_2\text{O}$-pretreated controls. In CSF of $^2\text{H}_2\text{O}$-pretreated mouse models of PD and in patients with PD, rates of appearance and disappearance of ^2H-labeled CHGB, soluble APP and SNCA were lower than those in healthy $^2\text{H}_2\text{O}$-pretreated controls. Planned work by KineMed Inc. includes developing the approach to diagnose PD, ALS, Huntington's disease (HD) and Alzheimer's disease (AD).</p> <p>C2N Diagnostics LLC's ^{13}C-labeling technology is in preclinical development to monitor β-amyloid levels in CSF as a measure of treatment response in AD.</p> <p>SciBX 5(36); doi:10.1038/scibx.2012.957 Published online Sept. 13, 2012</p>	Patented by the University of California, Berkeley; licensed to KineMed; available for licensing or partnering	<p>Fanara, P. <i>et al. J. Clin. Invest.</i>; published online Aug. 27, 2012; doi:10.1172/JCI64575</p> <p>Contact: Patrizia Fanara, KineMed Inc., Emeryville, Calif. e-mail: pfanara@kinemed.com</p>